Microphthalmia and anophthalmia (MA) are severe developmental eye anomalies, many of which are likely to have an underlying genetic cause. More than 30 genes have been described, each of which is responsible for a small percentage of these anomalies. Among these, is the FOXE3 gene, which was initially described in individuals with dominantly inherited anterior segment dysgenesis and, subsequently, associated with recessively inherited primary aphakia, sclerocornea and microphthalmia. In this work, we describe 8 individuals presenting with an MA phenotype. Among them, 7 are carrying biallelic recessive FOXE3 mutations and 2 of these have novel mutations: p.(Ala78Thr) and p.(Arg104Cys). The last of our patients is carrying in the heterozygous state the recessive p.(Arg90Leu) mutation in the FOXE3 gene. To further understand FOXE3 involvement in this wide spectrum of ocular anomalies with 2 different patterns of inheritance, we reviewed all individuals with ocular abnormalities described in the literature for which a FOXE3 mutation was identified. This review demonstrates that correlations exist between the mutation type, mode of inheritance and the phenotype severity. Furthermore, understanding the genetic basis of these conditions will contribute to overall understanding of eye development, improve the quality of care, genetic counseling and, in future, genebased therapies.
MA malformations represent the most severe ocular anomalies and their prevalence is estimated to be between 0.6 and 3.2/10 000 infants. 2 Anophthalmia refers to complete absence of the globe in the presence of ocular adnexa, whereas microphthalmia refers to a reduced total axial length of the globe that is at least 2 standard deviations below the mean for age. Microphthalmia is classified as simple, or complex, when associated with anterior and/or posterior segment dysgenesis, and graded depending on the degree of axial length reduction. Microphthalmia is often associated with coloboma which corresponds to the failure of closure of the optic fissure, extending inferonasally from the anterior to the posterior portion of the eye, during embryogenesis. Coloboma can affect the vision especially when located in the posterior segment of the eye, and encroaching on the visual axis or involving the optic nerve.
The visual consequences of these ocular developmental defects are highly dependent on the associated ocular anomalies and unilateral or bilateral involvement. For example, Shah et al 3 reported that 81% of microphthalmic eyes and 93% of microphthalmic eyes with coloboma were considered to have reduced vision. In a cohort of 98 patients with congenital corneal opacities (3/4 of whom had
Peters' anomaly), the best corrected visual acuity was impaired in 81% of affected eyes of bilaterally affected patients. 4 In addition, these ocular anomalies can be isolated or associated with extraocular anomalies. 5 Although diverse, genetic origin appears to be the predominant cause of congenital ocular anomalies and recent advances in DNA sequencing technologies have significantly increased our knowledge of the underlying MA genes. 6 The importance of their recognition and understanding is undeniable in terms of genetic counseling and prenatal diagnosis. Nevertheless, despite the identification of more than 30 genes in MA, mutations in each of these genes explain the symptoms in only a small percentage of patients. Indeed, overall the genetic cause is determined in around 30% of all MA patients, higher in severe MA cases. [5] [6] [7] The major gene still remains the SOX2 gene (MIM#184429), contributing to the cause in 10% to 15% of individuals usually with a severe MA phenotype, then OTX2 (MIM#600037) (2%-5%), RAX (MIM#601881) (3%), PAX6 (MIM#607108) (2%) and FOXE3 (MIM#601094) (2.5%). 6 The main genes involved in ASD are PAX6 (MIM#607108), CYP1B1 (MIM*601771) PITX2 (MIM*601542), FOXC1 (MIM*601090) and also FOXE3 (MIM#601094). 1 Only a few studies have determined the mutation detection rate using whole exome sequencing (WES). Deml et al 8 screened 28 probands affected by microphthalmia, anophthalmia and coloboma with no mutations in SOX2 or FOXE3. They analyzed 83 genes involved in ocular development and identified mutations in 3 patients (11%).
Weh et al 9 screened 27 patients affected by Peters' anomaly by WES and found 6 causative mutations (22%). Thus, to date, WES approach did not demonstrate a much higher mutation detection rate in patients with ocular developmental defects compared with the targeting sequencing of the main known genes. This approach had mainly led to the identification of new genes in particular pedigrees. [10] [11] [12] The FOXE3 gene encodes a transcription factor of 319 amino acids with a DNA-binding domain, the forkhead domain, located from amino acid 71 to 165. 13 FOXE3 is specifically expressed during lens development in humans, mouse and zebrafish. [14] [15] [16] Homozygous Foxe3 mutations were first identified in dyl/dyl mice displaying spontaneous microphthalmia associated with anterior segment abnormalities analogous to Peters' anomaly and cataract in the humans. 14 The biallelic mutation identified in this dyl murine model is located in the Foxe3 forkhead domain and prevents the binding of the Foxe3 protein to its DNA targets. 13 In humans, mutations in FOXE3 were initially described in individuals with dominantly inherited anterior segment dysgeneses. 13, 15 Subsequently, biallelic mutations were associated with primary congenital aphakia 20 and microphthalmia. 21 In addition, Kuang et al 22 recently suggested that specific mutations located in a particular region of the forkhead domain (amino acids 137-164) may be responsible for familial forms of thoracic aorta dilatation (TAAD).
Thus, the potential role of FOXE3 in a wide range of phenotypes with different patterns of inheritance prompted us to review all the individuals with ocular anomalies for which a FOXE3 mutation was identified in our laboratory and to compare this with published cases, to determine any genotype-phenotype correlation associated with mutations of this gene.
| METHODS
This study was designed in compliance with the tenets of the Declaration of Helsinki and patient enrollment had approval by our local are predicted to lead to a C-terminal extension of the protein, while preserving the entire FOXE3 sequence. Of note, a 3 0 end frameshift mutation (p.(Leu315AlafsTer117)) described here (Table 1 ) also results in a C-terminal extension with a conserved FOXE3 sequence (excepted for the 5 last amino acids of the protein) while all the other frameshift mutations described here are otherwise truncating.
| Monoallelic FOXE3 mutations
Among the 21 patients described with a unique FOXE3 mutation, 17 have a no-stop mutation and 2 cases (an index case and a parent of that case) have the frameshift mutation p.(Leu315AlafsTer117),
which similarly results in a C-terminal extension of the protein (Table 1) cannot be completely excluded). As the p.(Arg90Leu) mutation is thought to be associated with recessive inheritance, these 2 latter patients were excluded from our genotype-phenotype correlation studies.
Of the 19 patients analyzed, 18 showed isolated, but variable anterior segment anomalies. Only 1 patient reported in the literature 21 with a "dominant" mutation in the FOXE3 gene displayed a severe ocular phenotype. This patient had the no-stop p.
(Ter320Argext*72) mutation and bilateral complex microphthalmia, whereas her affected relatives demonstrated milder ocular phenotypes (anterior segment anomalies) (Table 1) .
Thus, the vast majority of patients with a dominant form (18/19, namely 95%) have isolated anterior segment dysgeneses, and all harbored a mutation leading to a C-terminal extension of the protein.
| Biallelic FOXE3 mutations
A total of 102 patients with a biallelic FOXE3 mutation are reported here (Table 2 ). Clinical and genetic data for all these patients and their relatives are summarized in Table 2 . Among them, 7 are new patients from our cohort and 2 of these have novel mutations: c.232G > A (p. (Table 3) . It is worth noting that all relatives heterozygous for these mutations are asymptomatic, suggesting a recessive mode of inheritance.
The analysis of the mutation type and the phenotype severity in the recessive forms ( Statistical analyses of the data above (Table 4) show that the FOXE3 mutation type has a strong influence on the severity of the Finally, association of truncating and missense mutations with recessive inheritance in contrast to the "elongating" mutations that appear exclusively dominant suggests that pathogenic effects are driven by distinct mechanisms. Recent work 24 has been suggested. 22 Thus, it has been hypothesized that the missense mutations position in the forkhead domain could have an impact on both the mode of transmission and the phenotype: a recessive ocular vs a dominant vascular phenotype. However, we can see that several individuals (7 in total) reported by Saboo et al 25 and in our study (mother of patient 5, Table 2 ) were heterozygous for the missense mutation p.(Gly158Arg) located in the 3 0 region of the forkhead domain (Figure 1 ), but did not demonstrate any aortic dilatation.
In conclusion, this review demonstrates the presence of genotype-phenotype correlations for FOXE3 mutations in congenital ocular abnormalities. These correlations will assist both in interpreting the molecular data of FOXE3 analysis when the phenotype is known, and in predicting phenotype and mode of inheritance when knowing the genotype in a family. Moreover, these correlations lay the foundations for exploring in more detail the effects of potential modifying factors that could influence the ocular phenotype, improving our understanding of eye morphogenesis and ocular genetic diseases in general.
